Drug intelligence / Profile preview

Dosmit

Development stage: Unknown
Lead developer: Guangzhou Welman Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

Dosmit (多司马酯) is a plant-derived small molecule gastroprotective agent developed by Guangzhou Welman Pharmaceutical. Marketed under the brand name Wei Duo Mei (卫多美), it is specifically indicated for the treatment and protection of gastrointestinal mucosal injury. The drug is described as a globally exclusive product that functions as a mucosal protective agent, though its specific molecular mechanism of action is not publicly detailed in standard pharmacological databases. It is administered orally in tablet form and has received regulatory approval in China, where it is used to repair and protect the gastric and intestinal lining.

Brand names: Wei Duo Mei卫多美
Other names: Dosmit Tablets多司马酯Duosimazhi多司马酯片

Beyond the preview

Go deeper on Dosmit.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Dosmit.

Explore the full profile